Holen Sie sich die Stockscreener-App
0.5349
4.55%
0.0233
Schlusskurs vom Vortag:
$0.5116
Offen:
$0.523
24-Stunden-Volumen:
89,836
Relative Volume:
1.75
Marktkapitalisierung:
$9.96M
Einnahmen:
$2.82M
Nettoeinkommen (Verlust:
$-14.20M
KGV:
-0.6293
EPS:
-0.85
Netto-Cashflow:
$-15.13M
1W Leistung:
+10.06%
1M Leistung:
-8.25%
6M Leistung:
-41.87%
1J Leistung:
-47.56%
1-Tages-Spanne:
$0.50
$0.5426
1-Wochen-Bereich:
$0.471
$0.5449
52-Wochen-Spanne:
$0.45
$1.27
Talphera Inc Stock (TLPH) Company Profile
Firmenname
Talphera Inc
Sektor
Telefon
650-216-3500
Adresse
1850 GATEWAY DRIVE, SAN MATEO
Vergleichen Sie TLPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.5349 | 9.96M | 2.82M | -14.20M | -15.13M | -0.85 |
|
ZTS
Zoetis Inc
|
157.44 | 68.46B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.32 | 47.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.70 | 45.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.19 | 17.90B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.60 | 13.14B | 2.76B | 1.11B | 898.10M | 22.77 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2020-07-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-11-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-04-24 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-15 | Eingeleitet | Credit Suisse | Outperform |
| 2018-10-23 | Eingeleitet | B. Riley FBR | Buy |
| 2017-10-13 | Herabstufung | Jefferies | Buy → Hold |
| 2017-10-13 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-07-14 | Fortgesetzt | Jefferies | Buy |
| 2016-09-15 | Bestätigt | ROTH Capital | Buy |
| 2016-08-05 | Herabstufung | Stifel | Buy → Hold |
| 2015-10-30 | Hochstufung | Jefferies | Hold → Buy |
| 2015-10-05 | Bestätigt | ROTH Capital | Buy |
| 2015-09-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-10 | Fortgesetzt | ROTH Capital | Buy |
| 2015-05-06 | Bestätigt | Mizuho | Neutral |
| 2015-05-05 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-03-10 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-03-09 | Herabstufung | Mizuho | Buy → Neutral |
Alle ansehen
Talphera Inc Aktie (TLPH) Neueste Nachrichten
HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA approves Talphera’s reduced NEPHRO CRRT study size - Investing.com India
Talphera reports Q4 EPS (7c) vs. (25c) last year - TipRanks
FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% - Stock Titan
TLPH stock touches 52-week low at $0.5 amid market challenges - Investing.com
Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall - MarketScreener
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million - PR Newswire
Earnings Outlook For Talphera - Benzinga
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 - Longview News-Journal
Talphera to Unveil 2024 Performance: Key Financial Results and Strategic Updates Coming March 31 - Stock Titan
Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com
Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter
Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register
RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World
Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN
Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World
FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada
FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria
FDA to review Talphera's request to amend NEPHRO study - Investing.com
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online
TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK
TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com
Talphera faces Nasdaq delisting over share price rule - Investing.com
Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK
Finanzdaten der Talphera Inc-Aktie (TLPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Talphera Inc-Aktie (TLPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Aslam Shakil | Chief Medical Officer |
Jun 14 '24 |
Buy |
1.07 |
5,000 |
5,357 |
37,695 |
| Aslam Shakil | Chief Medical Officer |
Jun 13 '24 |
Buy |
0.98 |
695 |
681 |
32,695 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Dec 05 '24 |
Buy |
0.64 |
5,000 |
3,200 |
208,066 |
| ASADORIAN RAFFI | Chief Financial Officer |
Dec 02 '24 |
Sale |
0.77 |
155 |
119 |
37,578 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Nov 27 '24 |
Buy |
0.73 |
5,000 |
3,650 |
203,066 |
3.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):